Combination of apatinib and docetaxel in treating advanced non-squamous non-small cell lung cancer patients with wild-type EGFR: a multi-center, phase II trial

BACKGROUND: This trial aimed to investigate the treatment response, survival profiles and treatment-related adverse events (AEs) of apatinib plus docetaxel in advanced non-squamous non-small cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR). METHODS: Thirty adv...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yong, Miao, Liyun, Wang, Zhaoxia, Shi, Meiqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330342/
https://www.ncbi.nlm.nih.gov/pubmed/32642151
http://dx.doi.org/10.21037/jtd.2020.03.54

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7330342/
https://www.ncbi.nlm.nih.gov/pubmed/32642151
http://dx.doi.org/10.21037/jtd.2020.03.54

Ejemplares similares